Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Breast cancer and negative lymph nodes~2. HLA-A2+ and/or HLA-A3+ to receive the vaccine. HLA-A2-, HLA-A3- patients will be eligible to be included in the control group.~3. Immunologically intact with a good performance status (defined below).~4. Without evidence of disease.~5. Patients may enroll while receiving appropriate hormonal therapy for their disease.~6. Completion of all standard first-line therapies (but may still be on hormonal therapy)~Exclusion Criteria:~1. HLA-A2- and/or HLA-A3- patients will not be vaccinated~2. Anergic by the Mantoux panel of recall antigens~3. Receiving immunosuppressive therapy~4. In poor health (Karnofsky \<60%, ECOG \>2)~5. Tbili \>1.5 mg/dL and creatinine\>2 mg/dL~6. Pregnancy (urine HCG)~7. Active metastatic disease~8. Involved in other experimental protocols (unless approval is first obtained by the other study PI)~9. Refusal of standard therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine (Type: EXPERIMENTAL): HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
- Control/observation (Type: NO_INTERVENTION): HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.

Based on this trial design, predict the completion outcome and termination type (if applicable).